AB Science   Report issue

For profit Phase 2 Phase 3
Founded: Paris France (2001)

Organization Overview

First Clinical Trial
2004
NCT00831922
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

AB Science

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Amyotrophic Lateral Sclerosis (Phase 3)

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Asthma (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Colorectal Neoplasms (Phase 3)

Coronavirus Infections (Phase 2)

Gastrointestinal Stromal Tumors (Phase 3)

Mastocytosis (Phase 3)

Mastocytosis, Systemic (Phase 3)

Melanoma (Phase 3)

Motor Neuron Disease (Phase 3)

Multiple Myeloma (Phase 3)

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Chronic Progressive (Phase 3)

Neoplasm Metastasis (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 3)

Psoriasis (Phase 2)

Recurrence (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 38
  • # of Trial APIs: 20